Tourmaline Bio Inc (TRML) Stock Price, Quote & News

Company Profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid e...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 481 9832

Website: www.tourmalinebio.com

Address:

27 West 24th Street, Suite 702, New York, United States

Dave_100 Sep. 9 at 8:50 PM

$ESPR if you look at $TRML and what Novartis just paid for it. Hard to believe $ESPR isn’t worth multiples of that with a fully approved drug, over $500M in worldwide sales this year, favorable European guidelines recommendations and US update to come plus great payer coverage, plus $ESPR has a pipeline just like $TRML does.

1 · Reply

RunnerSignals Sep. 9 at 8:10 PM

Today Top Movers! $CWD $TRML $WOLF $YOUL $FCEL crypto pivot, buyout, bankruptcy exit, earnings beat and clean energy buzz https://stocksrunner.com/news/2025-09-09-todays-top-gainers-stocks-up-on-manda-bankruptcy-exit-and-earnings

1 · Reply

topstockalerts Sep. 9 at 8:08 PM

Top Gainers PT2 $JEM $MMA $NAKA $PTNM $TRML

0 · Reply

anachartanalyst Sep. 9 at 8:02 PM

$TRML https://anachart.com/wp-content/uploads/ana_temp/1757448118_soc-img.jpg

0 · Reply

kennastrong Sep. 9 at 7:56 PM

$TRML NXXT early innings vibe getting stronger higher volume on up days softer fades on down days classic power trend

0 · Reply

JarvisFlow Sep. 9 at 7:54 PM

LifeSci Capital has adjusted their stance on Tourmaline Bio ( $TRML ), setting the rating to Market Perform with a target price of 48.

0 · Reply

GluttonBoy Sep. 9 at 7:36 PM

TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play Watching these: $CDTG $MMA $PTNM $NAKA $TRML

0 · Reply

Laurapicksright Sep. 9 at 7:31 PM

$IINN Give that news should squeeze with $ISPC $TRML $NAKA $PRPH 😍😍😍

0 · Reply

Gmblr777 Sep. 9 at 7:09 PM

$TRML why it’s so flat?

0 · Reply

BiotechBonesaw Sep. 9 at 6:11 PM

$TRML today, $TNXP & $NUVB & $IXHL & $ALT tomorrow 🚀

0 · Reply

This Small Biotech Stock Is Surging Today. Here's Why.

Sep 9, 2025, 8:58 AM EDT - 7 hours ago

Tourmaline Bio surges after Novartis $1.4 billion acquisition; analysts see strong fit

NVS

Sep 9, 2025, 7:28 AM EDT - 9 hours ago

This Biopharma Stock Is Soaring 58%. Novartis Is Acquiring It.

NVS

Sep 9, 2025, 5:39 AM EDT - 11 hours ago

Novartis to buy U.S. biotech in latest deal targeting firms in $1 billion to $3 billion range

NVS

Sep 9, 2025, 2:02 AM EDT - 14 hours ago

Novartis Agrees to Buy Tourmaline Bio in $1.4 Billion-Dollar Deal

NVS

Sep 9, 2025, 1:15 AM EDT - 15 hours ago

Novartis to acquire Tourmaline Bio in deal valuing it at $1.4 billion

NVS

Sep 9, 2025, 1:03 AM EDT - 15 hours ago

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

NVS

Sep 9, 2025, 1:00 AM EDT - 15 hours ago

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

NVS

Aug 31, 2025, 10:23 AM EDT - 9 days ago

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

Aug 13, 2025, 7:00 AM EDT - 27 days ago

Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

May 20, 2025, 4:51 PM EDT - 3 months ago

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 19, 2025, 4:05 PM EDT - 4 months ago

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 2, 2025, 7:30 AM EDT - 4 months ago

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

Mar 13, 2025, 7:30 AM EDT - 6 months ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Mar 3, 2025, 7:15 AM EST - 6 months ago

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

Jan 10, 2025, 7:30 AM EST - 8 months ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

Dec 10, 2024, 8:30 AM EST - 9 months ago

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

Nov 14, 2024, 7:30 AM EST - 10 months ago

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

Nov 7, 2024, 7:30 AM EST - 10 months ago

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 31, 2024, 7:30 AM EDT - 11 months ago

Tourmaline Bio to Present at Upcoming Investor Conferences

Oct 15, 2024, 7:30 AM EDT - 11 months ago

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

Oct 13, 2024, 10:29 AM EDT - 11 months ago

Tourmaline Bio: Looking To Go Beyond FcRn Inhibition With IL-6 Targeting

Oct 11, 2024, 7:30 AM EDT - 11 months ago

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

Oct 8, 2024, 7:30 AM EDT - 1 year ago

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 2, 2024, 4:30 PM EDT - 1 year ago

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

Jun 27, 2024, 8:05 AM EDT - 1 year ago

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

May 23, 2024, 7:10 AM EDT - 1 year ago

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

May 13, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Feb 1, 2024, 8:00 AM EST - 1 year ago

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Jan 29, 2024, 4:01 PM EST - 1 year ago

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jan 25, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

Jan 24, 2024, 4:05 PM EST - 1 year ago

Tourmaline Bio Announces Proposed Public Offering of Common Stock

Jan 8, 2024, 7:00 AM EST - 1 year ago

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

Dec 15, 2023, 4:00 PM EST - 1 year ago

Tourmaline Bio added to the NASDAQ Biotechnology Index

Dec 14, 2023, 7:30 AM EST - 1 year ago

Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board

Nov 1, 2023, 2:09 PM EDT - 2 years ago

Tourmaline Bio: TED And ASCVD Targeting With Differentiated IL-6

Oct 19, 2023, 5:37 PM EDT - 2 years ago

Tourmaline Bio Announces Closing of Merger with Talaris Therapeutics and Concurrent Private Placement of $75 Million

Oct 17, 2023, 5:47 PM EDT - 2 years ago

Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

Oct 6, 2023, 5:09 PM EDT - 2 years ago

Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

Oct 4, 2023, 8:30 AM EDT - 2 years ago

New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

Sep 28, 2023, 2:47 PM EDT - 2 years ago

TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS

Jun 22, 2023, 7:30 AM EDT - 2 years ago

Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement

May 26, 2023, 7:00 AM EDT - 2 years ago

Talaris Therapeutics Announces Leadership Transition

Feb 16, 2023, 7:00 AM EST - 2 years ago

Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Dave_100 Sep. 9 at 8:50 PM

1 · Reply

RunnerSignals Sep. 9 at 8:10 PM

1 · Reply

topstockalerts Sep. 9 at 8:08 PM

Top Gainers PT2 $JEM $MMA $NAKA $PTNM $TRML

0 · Reply

anachartanalyst Sep. 9 at 8:02 PM

$TRML https://anachart.com/wp-content/uploads/ana_temp/1757448118_soc-img.jpg

0 · Reply

kennastrong Sep. 9 at 7:56 PM

$TRML NXXT early innings vibe getting stronger higher volume on up days softer fades on down days classic power trend

0 · Reply

JarvisFlow Sep. 9 at 7:54 PM

LifeSci Capital has adjusted their stance on Tourmaline Bio ( $TRML ), setting the rating to Market Perform with a target price of 48.

0 · Reply

GluttonBoy Sep. 9 at 7:36 PM

TAIT stock is at zero borrow with shorts trapped and about to have a historic squeeze 3M float with no dilution and is a profitable semiconductor play Watching these: $CDTG $MMA $PTNM $NAKA $TRML

0 · Reply

Laurapicksright Sep. 9 at 7:31 PM

$IINN Give that news should squeeze with $ISPC $TRML $NAKA $PRPH 😍😍😍

0 · Reply

Gmblr777 Sep. 9 at 7:09 PM

$TRML why it’s so flat?

0 · Reply

BiotechBonesaw Sep. 9 at 6:11 PM

$TRML today, $TNXP & $NUVB & $IXHL & $ALT tomorrow 🚀

0 · Reply

IanMaui Sep. 9 at 5:55 PM

$RADX $TRML shareholders rewarded today shortly after P2 readout. Congrats, $15 stock in July. https://stocktwits.com/masonat/message/627958421

0 · Reply

topstockalerts Sep. 9 at 5:05 PM

Top Gainers PT2 $PTNM $TRML $NBIS $WOLF $VERI

0 · Reply

WSRX Sep. 9 at 4:06 PM

$TRML so who’s going to jail?

1 · Reply

StockElementCorporation Sep. 9 at 3:31 PM

Mid day movers 📈 $TRML (+58%) $WOLF (+41%) $NBIS (+35%) $TECK (+13%) $UNH (+3.9%)

0 · Reply

topstockalerts Sep. 9 at 3:21 PM

$TRML not a bad place for a swing idea 💡

0 · Reply

topstockalerts Sep. 9 at 2:54 PM

Top Gainers PT2 $TRML $WOLF $QMMM $VERI $SBLX

0 · Reply

prismmarketview Sep. 9 at 2:53 PM

$TRML has been acquired by Novartis for $48 per share. Tourmaline is focused on developing pacibekitug, a targeted therapy to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease. #stocksinnews https://prismmarketview.com/traders-lens/tourmaline-bio-inc-2/

0 · Reply

topstockalerts Sep. 9 at 2:25 PM

$TRML strong watch at these levels

0 · Reply

dogDazeSummer Sep. 9 at 2:21 PM

A mere week after reporting (poster) for ongoing P2 data at European Society of Cardiology, $TRML gets $1.2B buyout from $NVS Its IL6 mab showed reductions in C reactive protein in patients with chronic kidney disease. Runway cash into 2027. $XBI chart looks golden and non controversial pipeline type biotech is in play. Pipeline based / Euro buyer. https://www.tourmalinebio.com $IFRX

1 · Reply

BobGood Sep. 9 at 2:19 PM

$AMRN Congrats to $TRML bought by $NVS.. Do we still believe NVS may be a potential buyer of $AMRN?? $TRML doesn't have any FDA approved Rx with about 25M outstanding shares, but still worth $1.5B ..absolutely insane...wow.. But $AMRN has so many positives but still something is missing... What's going on inside $AMRN? IMHO, we may not see a long theory with lots of glittering markings about NVS/AMRN/Recordti connections in EU etc..at least for today !!! (no offense) Attached $TRML's pipeline below for reference..

1 · Reply

topstockalerts Sep. 9 at 1:59 PM

$TRML strong watch for today..

0 · Reply

Erg123 Sep. 9 at 1:50 PM

$TRML what’s the plan now? 😂 ride or sell it?

1 · Reply

Market Cap	687.00M
Revenue (ttm)	0.00
Net Income (ttm)	-73.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	22,621,773
Avg Vol	205,268
Day's Range	N/A - N/A
Shares Out	25.69M
Stochastic %K	95%
Beta	2.04
Analysts	Strong Sell
Price Target	$56.20